The Mount Sinai Hospital / Mount Sinai School of Medicine Jul 18 2025 In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief. These findings from two pivotal phase 3 trials known as GALAXI 2 and 3, published today in The